> The Spanish region of Valencia has resumed cervical cancer vaccinations using Merck's Gardasil, a health authority spokeswoman told Reuters, though one batch is still suspended and under investigation. Report
> Generics maker Pharmacare Premium plans to invest €10 million in a new Malta plant that will employ 60 people when it begins operating next year. Report
> Swedish pharma Orexo AB said it has inked a distribution agreement with Israel's Neopharm, giving the latter exclusive rights to sell Orexo's cancer pain treatment Abstral in Israel. Report
> Roche has had its membership to the Association of the British Pharmaceutical Industry reinstated after serving a seven month suspension for breaching its code of convention. Report
> Warren Buffett's Berkshire Hathaway reduced its stake in Johnson & Johnson by 54 percent to 28.6 million shares in the three months ended Dec. Report
> NeuroSearch is getting a capital injection of $22 million after signing a new R&D pact with Eli Lilly. Report
> A group of investors has stepped in to buy $42 million worth of shares in Affymax. The private placement gives the developer added funds for the late-stage development of Hematide. Report
> Breaking a therapeutic drought that has stretched over more than four decades, Takeda says it has won the FDA's approval of its new gout drug Uloric. Report
> Canada's Bradmer Pharmaceuticals says the CRO it hired for a late-stage brain cancer study "has indicated that it is unable to meet the targets for site initiation and enrollment of sufficient patients in a timely manner." Report
> Bioengineering experts are urging the adoption of open technology platforms that will hasten the creation of genetic materials and new drugs. Report
> If you dig deep into the Star-Ledger's article on Merck's ambitious plans to jump into the biosimilar business, you'll find that it will depend a lot on the success of the development technology advanced by Glycofi, a little company that it snapped up in 2006. Report
And Finally... A government report says the rate of dangerous staph infections has dropped dramatically in hospital intensive-care units, a rare encouraging sign about a hard-to-treat "superbug." Report